Search company, investor...

Karyopharm Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing small molecule modulators of nuclear transport. Karyopharm's selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor proteins in the nucleus, resulting in anti-cancer activity across multiple tumor types. In collaboration with many academic laboratories, SINEs targeting the major nuclear exporter XPO1 (also called CRM1) exert robust anti-cancer activity in diverse pre-clinical models of cancer. The lead SINE KPT-330 is in two Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being evaluated as an oral treatment for dogs with Non-Hodgkin's Lymphoma, one of the most common canine cancers. The Company is also testing SINEs in autoimmune, viral, and dermatological disorders. The company was founded in 2008 and is based in Newton Center, Massachusetts.

Headquarters Location

85 Wells Avenue 2/F

Newton Center, Massachusetts, 02459,

United States


Missing: Karyopharm Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Karyopharm Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Karyopharm Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Karyopharm Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Karyopharm Therapeutics Patents

Karyopharm Therapeutics has filed 41 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Human proteins
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Proteins, Clusters of differentiation, Autoimmune diseases, Human proteins


Application Date


Grant Date



Related Topics

Transcription factors, Proteins, Clusters of differentiation, Autoimmune diseases, Human proteins



Latest Karyopharm Therapeutics News

5 Companies Revolutionizing Blood Transportation Worldwide

Mar 20, 2023

The transportation of blood is a vital aspect of healthcare. Proper transportation of blood can mean the difference between life and death. Fortunately, there are several companies working to improve the transportation of blood, making it faster and safer for patients in need. Here are the top 5 companies revolutionizing blood transportation worldwide. 1.Zipline Zipline is a California-based startup that has pioneered the use of drones for the transportation of medical supplies, including blood. The company has partnered with several governments in Africa to deliver blood and other medical supplies to remote areas. Zipline drones can fly up to 100 km/hour and can deliver packages weighing up to 1.8 kilograms. The company has already completed over 50,000 flights and delivered more than 30,000 units of blood to hospitals and clinics in Rwanda and Ghana. 2. Bloodworks Northwest Bloodworks Northwest is a nonprofit blood center that serves the Pacific Northwest region of the United States. The company has developed a unique system for transporting blood in temperature-controlled boxes that keep blood at the required temperature during transit. The boxes are designed to maintain the temperature of the blood for up to 48 hours, allowing for safe transportation over long distances. 3. Karyopharm Therapeutics Karyopharm Therapeutics is a biopharmaceutical company that has developed a novel drug delivery system called Selective Inhibitor of Nuclear Export (SINE). The system allows for the targeted delivery of drugs to specific cells in the body. The company is currently testing the system for the transportation of blood to patients with sickle cell disease. The SINE system has the potential to revolutionize the treatment of sickle cell disease, which affects millions of people worldwide. 4. B Medical Systems B Medical Systems is a global manufacturer and distributor of medical cold chain solutions. Based in Hosingen, Luxembourg, the company was established in 1979, when the WHO approached Electrolux to provide a solution to store and transport vaccines safely around the world. Across its three business portfolios of Vaccine Cold Chain, Medical Refrigeration, and Blood Management solutions, the company offers 100+ products. B Medical Systems’ products are used across 140+ countries and have an installed base of more than half a million products worldwide. The company has been a long-trusted partner of global humanitarian organizations such as UNICEF, the WHO, the Red Cross, and more and has extensive experience working with Ministries of Health, hospitals, research organizations, universities, and blood transfusion companies across the world. B Medical Systems delivers its products worldwide and has subsidiaries in the USA and India. 5. Bloodbuy Bloodbuy is a healthcare technology company that has developed an online platform for the procurement and transportation of blood and other medical supplies. The platform connects hospitals and blood banks, making it easier for hospitals to find the blood they need and for blood banks to ensure that their supplies are being used efficiently. The platform also allows for real-time tracking of blood shipments, which helps to ensure that blood is delivered to its destination in a timely and safe manner. In conclusion, these five companies are revolutionizing blood transportation worldwide by using innovative technologies and platforms to ensure that blood reaches patients in need quickly and safely. Whether it’s through the use of drones, temperature-controlled boxes, novel drug delivery systems, or online platforms, these companies are making a significant impact on the transportation of blood, ultimately saving lives and improving healthcare outcomes.

Karyopharm Therapeutics Frequently Asked Questions (FAQ)

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Where is Karyopharm Therapeutics's headquarters?

    Karyopharm Therapeutics's headquarters is located at 85 Wells Avenue, Newton Center.

  • What is Karyopharm Therapeutics's latest funding round?

    Karyopharm Therapeutics's latest funding round is IPO.

  • How much did Karyopharm Therapeutics raise?

    Karyopharm Therapeutics raised a total of $100.2M.

  • Who are the investors of Karyopharm Therapeutics?

    Investors of Karyopharm Therapeutics include Delphi Ventures, Foresite Capital, New Leaf Venture Partners, Chione and Multiple Myeloma Research Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.